{'fraction_non_alphanumeric': 0.042704626334519574, 'fraction_numerical': 0.03416370106761566, 'mean_word_length': 5.221238938053097, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Single-Agent Irinotecan for Recurrent/Metastatic Colorectal Cancer: A Retrospective Analysis

Objective: To evaluate the efficacy, toxicity and factors affecting the survival rate of patients treated with irinotecan. Subjects and Methods: Data from the medical records of 74 patients who had recurrent/metastatic colorectal cancer treated with single-agent irinotecan were analyzed. Results: The mean age for all the patients was 56 years (range 19–77). Forty-one (55%) and 33 (45%) patients had recurrent and/or metastatic colon cancer, respectively. All the patients were treated with irinotecan 350 mg/m2 every 21 days. Grade 3–4 emesis, grade 3–4 diarrhea, grade 3–4 neutropenia and severe early cholinergic events developed in 7, 15, 7 and 1.3% of patients, respectively. One patient died due to acute renal failure. The overall response rate was 14% (complete response 5%, partial response 9%); 61% had stable response while another 25% had progressive disease. Patients with multiple metastatic foci, patients ≤50 years of age and patients with peritonitis carcinomatosa were shown to have worse outcomes than others. The median duration of response was 16.7 months. The median progression-free survival and overall survival were 4 and 14 months, respectively. Conclusion: The data show that irinotecan was useful in the treatment of recurrent/metastatic colorectal cancer with acceptable toxicity.